NYSE$GCTS

GCT Semiconductor Holding Inc · Q3 2025 earnings

Q3 2025 earnings · · After market close · Investor relations

Briefing

GCTS reported Q3 2025 a net loss of $13.8M, diluted EPS of $-0.25.

For Q3 2025, GCTS reported net loss was $13.8M, diluted EPS was $-0.25. The filing discusses operating performance, liquidity, and outlook in MD&A.

  • Net loss $13.8M.
  • Diluted EPS $-0.25.
  • MD&A covers R&D, cash runway, and sector-specific risks.

Headline financials

Total Revenue

$430K

Previous: $2.61M-83.5%
EPS (adj)

-$0.25

Previous: -$0.16-56.3%
Gross margin

-244.2%

No prior period
R&D expenses

$3.26M

Previous: $4.21M-22.6%
Sales & marketing

$1.05M

Previous: $949K+10.4%
General & admin

$3.9M

Previous: $2.38M+63.9%
Shares outstanding

55.5M

Previous: 45.6M+21.5%
Capital Expenditures

-$1.14M

Previous: -$185K-517.8%
Free Cash Flow

-$15M

Previous: -$7.31M-105.2%
Net Income

-$13.8M

Previous: -$7.12M-94.5%
Operating Income

-$9.25M

Previous: -$5.91M-56.5%
Gross Profit

-$1.05M

Previous: $1.63M-164.6%
Cash & Equivalents

$8.34M

Previous: $1.81M+360.4%
Total Assets

$24.3M

Previous: $22.6M+7.3%

Revenue & EPS history

GCT · Revenue · Quarterly

$430K

Q3 2025-83.5%vs Q3 2024
Beat estimate in 2 of 7 quarters(29%)
ActualEstimate

Revenue by segment

GCT · $4.48M total across 2 segments · Q3 2023

  • Product revenue
    $4.03M
  • Service revenue
    $450K

Forward guidance

Outlook focuses on cash runway, pipeline milestones, and cost discipline as the company works toward profitability.

Tailwinds

  • Cash and equivalents support operations into upcoming milestones.
  • Clinical or product pipeline progress noted in MD&A.

Headwinds

  • Ongoing operating losses and R&D spend pressure near-term earnings.
  • Financing, dilution, or partnership timing may affect liquidity.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 15 quarterly earnings reports · overlaid with Q3 2025

Historical avgQ3 2025

-5.0%

Avg return

Earnings day

-5.4%

Avg return

5 days after

-1.2%

Avg return

30 days after

22%

4 / 18 earnings

Positive

+1.2%

Q1 2026

Best reaction

-41.2%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+0.0%-6.5%
Q1 2026+1.2%+14.4%+58.7%
Q3 2025-12.6%-6.2%+0.0%
Q2 2025-8.3%-6.8%+13.5%
Q1 2025-41.2%-46.4%-37.7%
Q4 2024-16.7%-21.5%-30.6%
Q3 2024-9.1%-11.0%+3.9%
Q2 2024+0.8%-5.9%-24.7%
Q1 2024-4.3%-8.0%-5.7%
Q4 2023+0.0%+0.2%+0.4%
Q3 2023+0.1%+0.0%-0.2%
Q2 2023+0.0%+0.0%+1.1%
Q1 2023-0.2%-0.1%-0.1%
Q4 2022+0.0%+0.4%+0.9%
Q3 2022+0.0%+0.0%+0.1%
Q2 2022+0.0%+0.0%+0.5%
Q1 2022+0.0%+0.0%+0.0%
Q4 2021+0.1%-0.1%-0.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro